NCT06178770View on ClinicalTrials.gov

Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

CompletedOBSERVATIONAL
Enrollment

414

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions
Neovascular Age-related Macular Degeneration
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT06178770 - Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up | Biotech Hunter | Biotech Hunter